Effect of sitagliptin on vascular endothelial function in Type 2 diabetes

Effect of sitagliptin on vascular endothelial function in Type 2 diabetes - Effect of sitagliptin on vascular endothelial function in Type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009948

Enrollment

Registered

2013-02-04

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Sitagliptin treatment Group

First,starting sitagliptin treatment with 50mg. After 3 months,if the effect is not enough, raising sitagliptin dose to 100 mg. After additional 3 months,if the effect is not enough, adding combined m

First,starting glimepiride treatment with 0.5mg. After 3 months,if the effect is not enough, raising glimepiride dose to 1.0 mg. After additional 3 months,if the effect is not enough, adding combined

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Thirty years old or older 2)Patients treated PCI 3)Type 2 diabetes patients (HbA1c higher 6.5% below 8.4%) 4)Written consent for participation in this study

Exclusion criteria

Exclusion criteria: 1)Type 1 diabetes patients 2)Severe diabetic ketosis,diabetic coma,total coma 3)Severe infectious disease ,before or after surgery,and sever trauma 4)Severe renal dysfunction (eGFR<30mL/min or artificial dialysis) 5)cerebral infarction,cerebral apoplexy,subarachnoid bleeding,TIA in 3 months 6)Moderate or severe heart failure (NYHA III or IV) 7)Under treatment with oral diabetic medicine 8)Under treatment with insulin 9)Pregnant,lactating, possibly pregnant or planning to become pregnant women 10)Past medical history of hypersensitivity to sitagliptin or glimepiride 11)Patient considered as inadequate by the principal investigator

Design outcomes

Primary

Measure	Time frame
The changes in RH-PAT scores with Endo-PAT during 9 months	—

Secondary

Measure	Time frame
1)The changes in HMR(index of coronary peripheral circulation) from first PCI to 9 months 2)The rate of spasm with intracoronary acetylcholine after 9 months 3)The changes of following data during 9 months 8-OHdG,OPG,high sensitivity CRP CRP,small dense-LDL,high molecular adiponectin,RLP-C,NT-proBNP,TNF-a,IL-6 4)The changes in following data during 3,6,9 monnths HbA1c,fasting blood glucose,insulin,TC,HDL-C,TG,serum creatinine,urinary albumin excretion,eGFR 5)The changes in following data during 9 months echocardiographic study, PWV 6)The changes in following data and the frequency of following clinical condition Office blood pressure,body weight and frequency of significant variationof body weight, The frequency of hypoglycemia symptom	—

Measure

Time frame

1)The changes in HMR(index of coronary peripheral circulation) from first PCI to 9 months 2)The rate of spasm with intracoronary acetylcholine after 9 months 3)The changes of following data during 9 months 8-OHdG,OPG,high sensitivity CRP CRP,small dense-LDL,high molecular adiponectin,RLP-C,NT-proBNP,TNF-a,IL-6 4)The changes in following data during 3,6,9 monnths HbA1c,fasting blood glucose,insulin,TC,HDL-C,TG,serum creatinine,urinary albumin excretion,eGFR 5)The changes in following data during 9 months echocardiographic study, PWV 6)The changes in following data and the frequency of following clinical condition Office blood pressure,body weight and frequency of significant variationof body weight, The frequency of hypoglycemia symptom

—

Countries

Japan

Contacts

Public ContactHiroyuki Arashi

Tokyo Women's Medical University Cardiology

arahiro3130@gmail.com03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026